Authors
Tabassome Simon, Philippe Gabriel Steg, Martine Gilard, Didier Blanchard, Laurent Bonello, Michel Hanssen, Hervé Lardoux, Pierre Coste, Thierry Lefèvre, Elodie Drouet, Geneviève Mulak, Vincent Bataille, Jean Ferrières, Céline Verstuyft, Nicolas Danchin
Publication date
2011/2/8
Journal
Circulation
Volume
123
Issue
5
Pages
474-482
Publisher
Lippincott Williams & Wilkins
Description
Background
Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19). Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with clopidogrel to reduce the risk of gastrointestinal bleeding. This analysis compares treatment outcomes for patients in the French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) who did or did not receive clopidogrel and/or PPIs.
Methods and Results
The FAST-MI registry included 3670 patients (2744 clopidogrel- and PPI-naïve patients) presenting with definite MI. Patients were categorized according to use of clopidogrel and/or PPI within 48 hours after hospital admission. PPI use was not associated with an increased risk for any of the main in-hospital events (in-hospital survival, reinfarction, stroke, bleeding, and transfusion). Likewise, PPI treatment was not an independent predictor of 1-year …
Total citations
Scholar articles
T Simon, PG Steg, M Gilard, D Blanchard, L Bonello… - Circulation, 2011